- Home
- TARA vs EIC Comparison
TARA vs EIC Comparison
Compare TARA & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARA | EIC |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 223.3M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | TARA | EIC |
|---|---|---|
| Price | $5.11 | $9.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $21.67 | $12.63 |
| AVG Volume (30 Days) | ★ 673.0K | 167.2K |
| Earning Date | 05-07-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 13.91% |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $9.17 |
| 52 Week High | $7.82 | $14.83 |
Technical Indicators
Market Signals| Indicator | TARA | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 44.66 |
| Support Level | $4.95 | $9.25 |
| Resistance Level | $5.39 | $10.15 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 44.93 | 71.11 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.